Merck of Germany's Hunt For MS BTKi Partner Boosted By Evobrutinib Data
Executive Summary
German Merck tells Scrip its quest to find a partner for its Bruton’s tyrosine kinase inhibitor evobrutinib should be helped by positive 24-week Phase IIb data in relapsing multiple sclerosis.
You may also be interested in...
Mavenclad Poised To Be Big Mover For Merck KGaA
The German group is predicting sales of its new MS drug Mavenclad in the mid-triple digit million euro range worldwide in 2019 if all goes well across the Atlantic.
Mavenclad Is Merck KGaA Bright Spot As Q2 Sales Slip
With strong quarterly sales of Mavenclad in Europe, and a recent re-filing of the drug with the FDA, Merck KGaA continues to play the waiting game for top-line growth to return as it banks on the new addition to its MS franchise.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.